Clinical Trial

SLV-324 Treatment of Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-07-31; most recent amendment 2026-02-20.
Status change: Not Yet Recruiting → Recruiting 2025-09-10
Trial Details
NCT Number NCT07108114
Lead Sponsor Solve Therapeutics
Conditions Metastatic Solid Tumors
Enrollment 70 participants
Start Date 2025-08-25
Primary Completion 2027-05 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-23